11 completed, 10 recruiting, 4 terminated, 2 unknown. 12 Phase 2, 6 Not applicable, 4 Phase 1, 3 Phase 4, 2 Phase 3.
Follow Immunodeficiency: new trials by email Literature Review of Immunodeficiency trials Research Report on Immunodeficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-27 | 2026-10-22 |
| The Sequestration of Holistic Stress Management Techniques for Adults Holistic Medicine (HM) - Stress, Job, PTSD | Not applicable | Withdrawn | Goddess Zena I. Jones | 2026-01-26 | 2026-02-04 | |
| Vaccine-induced Immunity in Immunocompromised Patients Immunodeficiency | Recruiting | University of Cologne | 1000 | 2025-03-25 | 2026-05-12 | |
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3 - Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 100 | 2025-03-21 | 2026-04-15 |
| Clozapine-related Immunodeficiency in Parkinsons Disease blood test - Clozapine, Parkinson's Disease (PD) | Phase 4 | Recruiting | Centre Hospitalier Universitaire, Amiens | 24 | 2024-10-01 | 2025-11-19 |
| SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION Immunomodulation - Immunodeficiency, Autoimmune Diseases | Recruiting | Karolinska Institutet | 500 | 2024-01-01 | 2024-02-08 | |
| Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People 2 doses of HAV, At least one dose of HAV - Hepatitis A, Immunodeficiency | Phase 4 | Completed | LiuZhou People's Hospital | 392 | 2023-12-19 | 2025-12-31 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide - GATA2, Immunodeficiency | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2023-11-29 | 2026-08-11 |
| OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients Paxlovid 5 days, Paxlovid 10 days - COVID-19, Immunodeficiency | Phase 2 | Recruiting | Calmy Alexandra | 256 | 2023-04-27 | 2026-02-18 |
| OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial Paxlovid 5 days, Paxlovid 10 days, Veklury - COVID-19, Immunodeficiency | Phase 2 | Recruiting | ANRS, Emerging Infectious Diseases | 256 | 2023-04-27 | 2026-10-19 |
| Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation PCR based strategy, Standard care - Pneumonia, Ventilator-Associated, Pneumonia, Hospital-Acquired | Not applicable | Recruiting | University Hospital, Lille | 31 | 2023-03-28 | 2026-08-07 |
| A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF) - Immunodeficiency, Hematopoietic Stem Cell Transplantation | Phase 2 | Recruiting | National Cancer Institute (NCI) | 54 | 2023-02-23 | 2026-10-16 |
| ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals Access to Cue Health COVID-19 Remote testing and treatment for COVID-19 - Immunodeficiency, Immunosuppression | Not applicable | Terminated | Scripps Translational Science Institute | 2117 | 2022-12-22 | 2025-08-08 |
| Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients Blood draw - HIV Seropositivity, Immunodeficiency | Not applicable | Withdrawn | University Hospital, Ghent | 2021-05-10 | 2024-09-19 | |
| Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects Immunodeficiency | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 19 | 2020-11-12 | 2026-08-20 | |
| Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19) Omega 3/Nigella Sativa Oil, Omega 3/Nigella Sativa Oil/Indian Costus, Omega 3/Nigella Sativa Oil/Quinine pills - Covid19, Immunodeficiency | Phase 2 / Phase 3 | Completed | Beni-Suef University | 150 | 2020-09-20 | 2025-09-23 |
| Immunodeficiency in MS No Interventions - Multiple Sclerosis, Hypogammaglobulinemia | Unknown | Advanced Neurosciences Institute | 1500 | 2020-06-29 | 2020-06-25 | |
| European Alpha-Mannosidosis Participant Immunodeficiency, Skeletal Abnormalities | Terminated | CENTOGENE GmbH Rostock | 667 | 2018-08-20 | 2022-06-13 | |
| Immunodeficiency for Severe Epstein-Barr Virus Infection Epstein-Barr Virus Infections, Immunodeficiency | Completed | Children's Hospital of Fudan University | 100 | 2017-12-01 | 2023-02-09 | |
| Testing a Novel Dairy Protein to Counteract Immunosenescence Dairy protein - Immunodeficiency | Not applicable | Completed | University of California, Davis | 21 | 2016-08-01 | 2023-04-11 |
Showing 20 of 31. Sign in to see all of them.
Immunologic Deficiency Syndromes (31) · COVID-19 (5) · Anemia, Refractory, with Excess of Blasts (3) · Leukemia (3) · Agammaglobulinemia (2) · Autoimmune Diseases (2) · HIV Infections (2) · Lymphoma (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Acquired Immunodeficiency Syndrome (1) · Anemia (1) · Anemia, Sickle Cell (1) · Anxiety Disorders (1) · Arthritis (1)
Immune System Diseases (30) · Infections (11) · Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Virus Diseases (9) · RNA Virus Infections (7) · Respiratory Tract Diseases (7) · Bone Marrow Diseases (6) · Lung Diseases (6) · Lymphatic Diseases (6) · Pneumonia (6) · Respiratory Tract Infections (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Coronaviridae Infections (5) · Coronavirus Infections (5)
Busulfan (4) · Cyclophosphamide (4) · Tacrolimus (4) · Whole-Body Irradiation (4) · Antilymphocyte Serum (3) · Blood Specimen Collection (3) · Mycophenolic Acid (3) · fludarabine (3) · fludarabine phosphate (3) · nirmatrelvir and ritonavir drug combination (2) · AaIT neurotoxin, Androctonus australis (1) · Clinical Trials, Phase I as Topic (1) · Congresses as Topic (1) · Cyclosporine (1) · Cyclosporins (1)
National Cancer Institute (NCI) (4) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · ANRS, Emerging Infectious Diseases (1) · Advanced Neurosciences Institute (1) · Beijing 302 Hospital (1) · Beni-Suef University (1) · CENTOGENE GmbH Rostock (1) · Calmy Alexandra (1) · Centre Hospitalier Universitaire, Amiens (1) · Children's Hospital of Fudan University (1) · Children's Hospital of Philadelphia (1) · Fred Hutchinson Cancer Center (1) · Goddess Zena I. Jones (1) · Hospital Israelita Albert Einstein (1) · Johann Wolfgang Goethe University Hospital (1)
United States (15) · France (3) · China (2) · Germany (2) · Switzerland (2) · Belgium (1) · Brazil (1) · Italy (1) · Norway (1) · Saudi Arabia (1) · Sweden (1)
Danielle E Pregent-Arnold, M.D. (2) · Alexandra Calmy, MD PhD (1) · Andrew Gilman, MD (1) · Arthur W Nienhuis, MD (1) · Bhavisha A Patel, M.D. (1) · Christian C Yost, M.D. (1) · Dennis D Hickstein, M.D. (1) · Fu-Sheng Wang (1) · Gulbu Uzel, M.D. (1) · Irini Sereti, M.D. (1) · Jeannine S. McCune, PharmD (1) · Jinqiao Sun, Ph.D.,M.D (1) · John W. Sleasman, M.D. (1)
PMID 24077845, PMID 21508125, PMID 21816832, PMID 23344397, PMID 29047161, PMID 31089278, PMID 32556286, PMID 34477998, PMID 36251488, PMID 37595058, PMID 38194689, PMID 38935839, PMID 40503088, PMID 41175032, PMID 42492070
2023 (1), P01HL053749 (1)